• 31 MayBronstein, Gewirtz & Grossman LLC Urges Calix, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

• 31 MaySublime AI Law Mastery Unveiled to Resolve Historic Camp Lejeune Backlog (Veterans First For America)

• 31 MayKALDVIK AS (KLDVK): Q1 2026 Quarterly Update

• 31 MayPrecede Biosciences Presents New ASCO 2026 Data Demonstrating Ability of Precede Bio Insight™ to Decode MET-Driven Biology and Resistance in Advanced NSCLC

• 31 MayJames Altucher Spent Months Researching the Technology Behind the SpaceX IPO. He Put Everything Into One Presentation and Released It for Free

• 31 MayWhy AI Visibility Operating Systems Are Replacing Fragmented Marketing Strategies

• 31 MayImmatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer

• 31 MayJohnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, versus hormone therapy alone, potentially shifting a decades-long treatment paradigm

• 31 MayAI Is Reshaping Crypto Faster Than Anyone Expected as AIX Alpha’s New System Signals the Shift

• 31 MayRevolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer

• 31 MayImmunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma

• 31 MayReplimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

• 31 MaySlimTide Truth Revealed (2026 Official Website Risk Warning) Avoid Hidden Fees & Fake Complaints

• 31 MayAdtran Holdings, Inc.: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

• 31 MayNokia Corporation - Managers' transactions (Hanrahan)

• 31 MayNeuExcell Therapeutics Announces Encouraging Data of NXL-004 in Recurrent Malignant Glioma at 2026 ASCO